Avenacy Announces Launch of Tranexamic Acid Injection, USP in the U.S. Market

Represents the Company’s tenth product launch since inception in October 2023

SCHAUMBURG, Ill.--(BUSINESS WIRE)--Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, today announced it has launched Tranexamic Acid Injection, USP in the United States as a therapeutic generic equivalent for Cyklokapron^® as approved by the U.S. Food and Drug Administration. Tranexamic Acid Injection, USP is indicated in patients with hemophilia for short-term use (2 to 8 days) to reduce or prevent hemorrhage and reduce the need for replacement therapy during and following tooth extraction.

“In less than one year since starting Avenacy, we have launched ten essential injectable medications – a formidable achievement and testament to our commercial expertise in specialty pharmaceuticals,” said Jeff Yordon, Co-Founder and CEO of Avenacy. “Since our company’s inception in October 2023, we have aimed to quickly deliver safe, effective, quality specialty injectables to hospitals and providers across the U.S., and the launch of Tranexamic Acid injection marks another important step in fulfilling this mission. The rest of 2024 is poised to be a transformative year for the business, as we remain focused on launching several additional products.”

Avenacy's Tranexamic Acid Injection, USP is available in 1,000 mg/10 mL (100 mg per mL) 10-pack single-dose vials. In line with Avenacy’s mission to champion patient safety and streamline patient care, Tranexamic Acid Injection, USP will feature the Company’s highly differentiated packaging and labeling to support accurate medication selection.

Avenacy will begin shipping Tranexamic Acid Injection, USP to wholesale partners this week. The Company is supported by a global network of development and contract manufacturing partners that have undergone successful FDA inspections based on cGMP-standards.

Tranexamic Acid Injection, USP had U.S. sales of approximately $28 million for the twelve months ending in June 2023.¹

Please see link for Full Prescribing Information.

Cyklokapron^® is a registered trademark of Pfizer.

¹Source: IQVIA

About Avenacy

Avenacy is a U.S.-based specialty pharmaceutical company focused on supplying critical injectable medications used to treat patients in various medically supervised settings, from acute care hospitals to outpatient clinics and physician offices. Through a rigorous and optimized selection process, the Company is building out a pipeline of high-quality FDA approved injectable products in order to ensure a resilient portfolio that can meet the needs of today’s dynamic drug supply chain. With an experienced team, commitment to quality and reliability, and product offerings intended to facilitate safe and efficient patient care, Avenacy strives to be a trusted partner for essential medications.

Avenacy was launched in 2023 and is headquartered in Schaumburg, IL. For more information, please visit http://www.avenacy.com/.